Sentences with phrase «of tumor therapies»

Not exact matches

«In the long term, we want to be able to send energy to and communicate with implants all over the body, to record data from a variety of organs in many different ways, maybe even report on the conditions of tumors or cancer therapies,» Maharbiz says.

Jim Cramer sits down with the executive chairman of oncology giant Novocure to get the latest on its cutting - edge tumor therapy.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

«This approval will open the floodgates for these kinds of therapy to be used in many different leukemias, lymphomas, solid tumors, myelomas,» Dr. Prakash Satwani, a pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

Cambridge, MA — March 5, 2015 — Aura Biosciences, a biotech company developing highly tumor - targeted breakthrough therapies for rare cancers, has secured a $ 21M Series B round of funding.

Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.

Around four - fifths of prostate cancer patients have tumors with lots of PSMA for the therapy to bind to.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

Some weeks later, after radiation therapy that was designed to limit the extent of the surgery, he wrote to tell me that the doctors were astounded to learn that the tumor had been stopped cold by the radiation and that surgery would not be required.

He underwent surgery three times to remove tumors, each time followed by weeks of chemo - therapy.

In December 2017, writing in Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous models.

In October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapies.

Gene therapy procedures in humans have been linked to the onset of leukemia and various tumors, as well as sudden death.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

This method, sometimes called «liquid biopsy,» can provide guidance for treatment decisions, monitoring of cancer therapy, and organism - wide screening for the presence of nascent metastatic tumors in drug - treated cancer patients.

In the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the body.

«This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors.»

Revving up the immune system to combat a wide variety of tumor types may take cancer therapy in a new direction, says Khaled Barakat, a computational scientist at the University of Alberta in Canada, who was not involved in the study.

«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»

More precise application of immuno - therapies and the development of new approaches requires knowing the detailed immune landscape of individual patients and tumors.

Immune checkpoint blockade therapies use antibodies to counter the defensive tactics of tumor cells.

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therapies.

The researchers confirmed some of these findings by analyzing how effective radiation therapy was in 29 colon cancer tumors that metastasized to either the liver or lung.

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

«Next generation sequencing tools were used to profile patients» tumors,» said Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at UC San Diego Moores Cancer Center.

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Matching unique genetic information from cancer patients» tumors with treatment options — an emerging area of precision medicine efforts — often fails to identify all patients who may respond to certain therapies.

«For patients who have not responded to prior therapies, this drug now provides a very real chance to shrink their tumors and the hope of a lasting response to treatment.»

«HPV - active tumors have high expression of immunoregulatory genes and therefore may respond to immune checkpoint inhibitor therapy.

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

Along with the study's co-first authors, Drs. Aayoung Hong and Gatien Moriceau, Lo hypothesized that if they could identify the key tumor cell processes triggered by withdrawal of MAPK inhibitors, then scientists can exploit these process with existing or investigational drugs to trigger the maximal levels of tumor cell death immediately following cessation of the initial therapy.

This is one of the first research studies to highlight the importance of the location of the metastasis as well as the location of the original primary tumor, in predicting response to radiation therapy.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

The researchers found that withdrawal of MAPK therapies triggered a large build - up of MAPK signals to levels that proved stressful to the tumor cells.

Moffitt Cancer Center researchers have contributed to these advances by developing the first test that analyzes the sensitivity of tumors to radiation therapy.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

Conventional radiation with photons gave way to intensity - modulated radiation therapy, or IMRT, in which more precise beams of photons could be moved dozens or hundreds of times with varying intensities, attacking tumors in three dimensions with safer high doses.

Because it treats the whole brain, the therapy is thought to control the spread of tumors by treating both identifiable and hidden cancerous cells.

Now, researchers at Washington University School of Medicine in St. Louis have shown that cervical tumors that don't respond to radiation may be vulnerable to therapies that also attack the cancer's fuel supply.

«Given the devastating impact of cancer metastasis and the dire need for therapies to combat tumor spread, we're highly encouraged by these findings and excited about the therapeutic possibilities they open up.»

Again, using mouse models of glioblastoma — this time created from brain tumor cells that were resistant to the herpes virus — the therapy led to increased animal survival.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

The study also addressed another weakness of cancer - killing viruses, which is that not all brain tumors are susceptible to the therapy.

No targeted therapy has been approved for noninflammatory and inflammatory triple - negative breast cancer tumors, and the standard of therapy for these tumors is a combination of conventional cytotoxic chemotherapeutic agents.

This is particularly true for immunotherapy, in which characterization of tumor heterogeneity is essential for choosing the most effective therapy.

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

«Trying to understand as much as we can about genetic versus non-genetic determinants of tumor organization is key to our understanding of tumor propagation and to the design of new therapies.

Until now the use of adenoviruses in tumor therapy has been very limited.